479 related articles for article (PubMed ID: 28139294)
1. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
[TBL] [Abstract][Full Text] [Related]
2. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
3. Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice.
Miwa T; Sato S; Gullipalli D; Nangaku M; Song WC
J Immunol; 2013 Apr; 190(7):3552-9. PubMed ID: 23427256
[TBL] [Abstract][Full Text] [Related]
4. Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains.
Gilmore AC; Zhang Y; Cook HT; Lavin DP; Katti S; Wang Y; Johnson KK; Kim S; Pickering MC
Kidney Int; 2021 Feb; 99(2):396-404. PubMed ID: 33129896
[TBL] [Abstract][Full Text] [Related]
5. Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.
Ueda Y; Miwa T; Gullipalli D; Sato S; Ito D; Kim H; Palmer M; Song WC
J Am Soc Nephrol; 2018 Jul; 29(7):1928-1937. PubMed ID: 29858280
[No Abstract] [Full Text] [Related]
6. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis.
Lesher AM; Zhou L; Kimura Y; Sato S; Gullipalli D; Herbert AP; Barlow PN; Eberhardt HU; Skerka C; Zipfel PF; Hamano T; Miwa T; Tung KS; Song WC
J Am Soc Nephrol; 2013 Jan; 24(1):53-65. PubMed ID: 23204401
[TBL] [Abstract][Full Text] [Related]
7. Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency.
Ruseva MM; Vernon KA; Lesher AM; Schwaeble WJ; Ali YM; Botto M; Cook T; Song W; Stover CM; Pickering MC
J Am Soc Nephrol; 2013 Jan; 24(1):43-52. PubMed ID: 23184055
[TBL] [Abstract][Full Text] [Related]
8. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
[TBL] [Abstract][Full Text] [Related]
9. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
Ueda Y; Miwa T; Ito D; Kim H; Sato S; Gullipalli D; Zhou L; Golla M; Song D; Dunaief JL; Palmer MB; Song WC
Kidney Int; 2019 Jul; 96(1):67-79. PubMed ID: 30910380
[TBL] [Abstract][Full Text] [Related]
10. Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy.
Devalaraja-Narashimha K; Meagher K; Luo Y; Huang C; Kaplan T; Muthuswamy A; Halasz G; Casanova S; O'Brien J; Peyser Boiarsky R; McWhirter J; Gartner H; Bai Y; MacDonnell S; Liu C; Hu Y; Latuszek A; Wei Y; Prasad S; Huang T; Yancopoulos G; Murphy A; Olson W; Zambrowicz B; Macdonald L; Morton LG
J Am Soc Nephrol; 2021 Jan; 32(1):99-114. PubMed ID: 33288630
[TBL] [Abstract][Full Text] [Related]
11. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury.
Ruseva MM; Hughes TR; Donev RM; Sivasankar B; Pickering MC; Wu X; Harris CL; Morgan BP
Mol Immunol; 2009 Feb; 46(5):803-11. PubMed ID: 18947875
[TBL] [Abstract][Full Text] [Related]
12. Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5.
Freeley SJ; Popat RJ; Parmar K; Kolev M; Hunt BJ; Stover CM; Schwaeble W; Kemper C; Robson MG
J Pathol; 2016 Sep; 240(1):61-71. PubMed ID: 27235854
[TBL] [Abstract][Full Text] [Related]
13. C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.
Zhao F; Afonso S; Lindner S; Hartmann A; Löschmann I; Nilsson B; Ekdahl KN; Weber LT; Habbig S; Schalk G; Kirschfink M; Zipfel PF; Skerka C
Front Immunol; 2019; 10():1030. PubMed ID: 31214159
[TBL] [Abstract][Full Text] [Related]
14. C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh-/- Cfd-/- mice.
Zhang Y; Keenan A; Dai DF; May KS; Anderson EE; Lindorfer MA; Henrich JB; Pitcher GR; Taylor RP; Smith RJ
JCI Insight; 2020 May; 5(9):. PubMed ID: 32376801
[TBL] [Abstract][Full Text] [Related]
15. C3 dependent, C5 independent immune complex glomerulopathy in the mouse.
Sawtell NM; Hartman AL; Weiss MA; Pesce AJ; Michael JG
Lab Invest; 1988 Mar; 58(3):287-93. PubMed ID: 2964544
[TBL] [Abstract][Full Text] [Related]
16. Complement 5 Inhibition Ameliorates Hepatic Ischemia/reperfusion Injury in Mice, Dominantly via the C5a-mediated Cascade.
Kusakabe J; Hata K; Tamaki I; Tajima T; Miyauchi H; Wang Y; Nigmet Y; Okamura Y; Kubota T; Tanaka H; Tsuruyama T; Uemoto S
Transplantation; 2020 Oct; 104(10):2065-2077. PubMed ID: 32384381
[TBL] [Abstract][Full Text] [Related]
17. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily.
Wang X; Van Lookeren Campagne M; Katschke KJ; Gullipalli D; Miwa T; Ueda Y; Wang Y; Palmer M; Xing G; Song WC
J Am Soc Nephrol; 2018 Aug; 29(8):2053-2059. PubMed ID: 29895552
[No Abstract] [Full Text] [Related]
18. Critical role of C5a in sickle cell disease.
Vercellotti GM; Dalmasso AP; Schaid TR; Nguyen J; Chen C; Ericson ME; Abdulla F; Killeen T; Lindorfer MA; Taylor RP; Belcher JD
Am J Hematol; 2019 Mar; 94(3):327-337. PubMed ID: 30569594
[TBL] [Abstract][Full Text] [Related]
19. C3 glomerulopathy: A new complement-based entity.
de Lorenzo A; Tallón S; Hernández-Sevillano B; de Arriba G
Rev Clin Esp (Barc); 2014; 214(5):266-74. PubMed ID: 24576419
[TBL] [Abstract][Full Text] [Related]
20. The C5a receptor has a key role in immune complex glomerulonephritis in complement factor H-deficient mice.
Alexander JJ; Chaves L; Chang A; Quigg RJ
Kidney Int; 2012 Nov; 82(9):961-8. PubMed ID: 22832515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
